Share on LinkedInShare on LinkedIn

ARTICLE · 03 AUGUST 2015

Generic Labels Can Omit Orphan Drug Indications To Avoid Brand Exclusivity Rights

Otsuka argued that, in general, where a specific pediatric indication exists, that pediatric indication must be described under the "indications and usage" section of a drug label.

United StatesIntellectual Property

Otsuka Pharm. Co., Ltd. v. Burwell (D. Md. Apr. 29, 2015)

Two hours after the U.S. Food and Drug Administration (FDA) approved generic versions of Abilify® (aripiprazole) (excluding pediatric indications and dosage information), the U.S. District Court for the District of Maryland held a hearing on Plaintiff Otsuka Pharmaceutical's motion for a temporary restraining order (TRO) seeking to enjoin the FDA from granting further approvals and the generic companies from launching their generic products. Since the FDA had recently approved a pediatric indication for Abilify that is protected by orphan drug exclusivity, Otsuka argued that the FDA could not approve any generic form of Abilify within its seven-year period of orphan drug market exclusivity. The district court held, however, that the Food, Drug and Cosmetics Act (FDCA) likely did not support such a position and, as a result, denied Otsuka's request for emergency injunctive relief. Otsuka Pharmaceutical Co.,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from